![Salim Dhanji](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 10 M $ al 31/08/2026
Salim Zulifkar Dhanji is President, Chief Executive Officer & Director at ME Therapeutics Holdings, Inc. since 2023.
Dr. Dhanji is President at Perceptive Property Development since 2013.
Formerly, Dr. Dhanji was Director-Preclinical Research at Qu Biologics, Inc. from 2009 to 2014.
Education includes an undergraduate degree (2001) and a doctorate (2006) from the University of British Columbia.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 16/07/2026 | 4.175.143 ( 13,89 % ) | 10 M $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ME THERAPEUTICS HOLDINGS INC. | Director Ejecutivo | 09/03/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
Qu Biologics, Inc.
 Qu Biologics, Inc. BiotechnologyHealth Technology Develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer | Corporate Officer/Principal | 01/01/2014 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
University of British Columbia
 University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Qu Biologics, Inc.
Qu Biologics, Inc. BiotechnologyHealth Technology Develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer | Health Technology |
ME Therapeutics Holdings, Inc.
 ME Therapeutics Holdings, Inc. BiotechnologyHealth Technology Provides biotechnology and pharmaceutical services | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
